Albuminuria‐lowering effect of sodium‐glucose cotransporter 2 inhibitors could be partly attributable to the attenuation of tubular damage in type 2 diabetic patients

2020 ◽  
Vol 36 (7) ◽  
Author(s):  
Katsuyuki Yanagisawa ◽  
Ami Sotokawauchi ◽  
Yuri Nishino ◽  
Takanori Matsui ◽  
Nobuhiro Tahara ◽  
...  
Keyword(s):  
Diabetic Patients ◽  
Tubular Damage ◽  
Type 2 Diabetic Patients ◽  
Lowering Effect ◽  
Sodium Glucose Cotransporter ◽  
Type 2 Diabetic

scholarly journals Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?

2021 ◽  
Vol 8 ◽  
Author(s):  
Dan Xu ◽  
Owain Chandler ◽  
Cleo Wee ◽  
Chau Ho ◽  
Jacquita S. Affandi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Diabetic Patients ◽  
Atherosclerotic Cardiovascular Disease ◽  
Healthy Individuals ◽  
Type 2 Diabetic Patients ◽  
Sodium Glucose Cotransporter ◽  
Type 2 Diabetic

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively novel class of drug for treating type 2 diabetes mellitus (T2DM) that inhibits glucose reabsorption in the renal proximal tubule to promote glycosuria and reduce blood glucose levels. SGLT2i has been clinically indicated for treating T2DM, with numerous recent publications focussing on both primary and secondary prevention of cardiovascular and renal events in Type 2 diabetic patients. The most recent clinical trials showed that SGLT2i have moderately significant beneficial effects on atherosclerotic major adverse cardiovascular events (MACE) in patients with histories of atherosclerotic cardiovascular disease. In this review and analysis, SGLT2i have however demonstrated clinically significant benefits in reducing hospitalisation for heart failure and worsening of chronic kidney disease (CKD) irrespective of pre-existing atherosclerotic cardiovascular disease or previous heart failure history. A meta-analysis suggests that all SGLT2 inhibitors demonstrated the therapeutic benefit on all-cause and cardiovascular mortality, as shown in EMPAREG OUTCOME study with a significant decrease in myocardial infarction, without increased stroke risk. All the above clinical trial recruited type 2 diabetic patients. This article aims to postulate and review the possible primary prevention role of SGLT2i in healthy individuals by reviewing the current literature and provide a prospective overview. The emphasis will include primary prevention of Type 2 Diabetes, Heart Failure, CKD, Hypertension, Obesity and Dyslipidaemia in healthy individuals, whom are defined as healthy, low or intermediate risks patients.

Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients

2014 ◽  
Vol 30 (8) ◽  
pp. 736-741 ◽  
Author(s):  
Sang Soo Kim ◽  
Sang Heon Song ◽  
In Joo Kim ◽  
Won Jin Kim ◽  
Yun Kyung Jeon ◽  
...  
Keyword(s):  
Early Development ◽  
Diabetic Patients ◽  
Tubular Damage ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

2014 ◽  
Vol 124 (2) ◽  
pp. 499-508 ◽  
Author(s):  
Ele Ferrannini ◽  
Elza Muscelli ◽  
Silvia Frascerra ◽  
Simona Baldi ◽  
Andrea Mari ◽  
...  
Keyword(s):  
Metabolic Response ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Sodium Glucose Cotransporter ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document